Rekombinanter VEGF (Bevacizumab Biosimilar) Antikörper

Produktnummer ABIN7200653

Dieser Humanized Monoklonal Antikörper detektiert spezifisch VEGF (Bevacizumab Biosimilar) in FACS und in vivo. Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für Rekombinanter VEGF (Bevacizumab Biosimilar) Antikörper (ABIN7200653)

Target: VEGF (Bevacizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Humanized

Klonalität: Monoklonal

Konjugat: Dieser VEGF (Bevacizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-VEGF (Bevacizumab Biosimilar) Antikörper

Verwendungszweck: Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody

Spezifität: The monoclonal antibody Bevacizumab biosimilar specifically binds to the human VEGF-A.

Produktmerkmale: Bevacizumab, the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis inhibition and slows the growth of new blood vessels. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain. Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: The monoclonal antibody Bevacizumab biosimilar was produced in the bevacizumab biosimilar CHO stable cell line.

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by bevacizumab.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Lagerung: 4°C,-20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu VEGF (Bevacizumab Biosimilar)

Target: VEGF (Bevacizumab Biosimilar)

Andere Bezeichnung: Bevacizumab Biosimilar

Substanzklasse: Biosimilar